ArticleScience signaling2014
Combinatorial nanotherapeutics: rewiring, then killing, cancer cells.
Article in Science signaling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Combinatorial Therapy: Targeting CD133+ Glioma Stem-like Cells with a Polysaccharide-Prodrug Complex Functionalised Gold Nanocages.Biomedicines · 2024Article
- Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.Nanoscale horizons · 2020Review
- Reversing activity of cancer associated fibroblast for staged glycolipid micelles against internal breast tumor cells.Theranostics · 2019Article
- Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery.Annals of biomedical engineering · 2016Review
- Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.Oncotarget · 2016Article
- Recent advances of cocktail chemotherapy by combination drug delivery systems.Advanced drug delivery reviews · 2016Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors are inherently resilient and often develop resistance against cancer therapies, leading to poor patient outcomes. With the sophisticated analytical and computational tools now available, much has been revealed about how molecularly targeted drugs affect the biochemical networks of cancer cells, enabling the directed design of treatment regimens that can better thwart resistance. In this issue of Science Signaling, Morton et al. demonstrate a nanoparticle system capable of sequentially delivering two drugs: The first inhibits an oncogenic pathway to sensitize the cells to DNA damage-induced apoptosis; the second is a genotoxic drug that takes advantage of the vulnerable state of the cancer cells to kill them with enhanced efficiency.
Indexed as
Identifiers
24825918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.